drugset / Trial / NCT03150771
Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia
Phase 1
Completed
36 enrolled
Otsuka Pharmaceutical Development & Commercialization, Inc.
H. Lundbeck A/S · collab
Non-randomizedParallel-groupOpen-labelSupportive care
Summary
This trial will determine the Pharmacokinetics, safety and tolerability of single-dose Aripiprazole administered intramuscularly in adults with schizophrenia
Timeline
- Start
- 2017-06-14
- Primary completion
- 2018-04-18
- Completion
- 2018-05-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | — | Intramuscular |